#2146
Clinical Utility (CU) Evaluation of the Health-Related Quality-of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumors (NETs). QUALINETS Study
Introduction:
QLQ-GINET21 for pts with GI-NETs covers muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference:
15th Annual ENETSConcerence (2018)
Presenting Author:
Authors:
Gallego J,
Reig O,
Sastre J,
Garcia I,
Segura A,
Keywords:
neuroendocrine tumors,
Quality of Life,
QLQ-GINET21,
utility,
#1696
On-going Evaluation of The Clinical Utility of the Health-Related Quality-Of-Life (HRQoL) QLQ-GINET21 Questionnaire (QNR) in the Treatment of Patients (pts) with Gastrointestinal (GI) Neuroendocrine Tumours (NETs). QUALINETS Study
Introduction:
Outcome measures reported by pts help to weigh benefit/effect of a therapy on quality of life (QoL), provided that their utility in clinical practice is proved. There are few QoL QNRs for pts with NETs, like QLQ-GINET21, with 21 items assessing muscle/bone pain, body image, information, sexual function, symptoms, social function and disease-related concerns.
Conference:
14th Annual ENETSConcerence (2017)
Presenting Author:
Gallego J
Authors:
Gallego J,
Benavent M,
Reig �,
Sastre J,
Díaz-Pabón I,
Keywords:
neuroendocrine tumors,
QoL,
QLQ-GINET21,
utility,
#929
Prognostic Role of Smoking in Gastroenteropancreatic Neuroendocrine Tumors (GEP-NET)
Introduction:
Large retrospective series identified several prognostic factors for GEP-NET such as sex, race, age, primary localization, stage or tumor grade. Several studies suggested a prognostic role of smoking in many cancer types. However, no data has been reported in GEP-NET.
Conference:
11th Annual ENETSConcerence (2014)
Presenting Author:
Authors:
Pons F,
Mar I,
Gallego ,
Luque A,
González ,
Keywords:
smoking,
prognostic,
gastroenteropancreatic,
neuroendocrine tumor,